Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/23
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/23
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/23
Werewolf Therapeutics: A Clinical Stage Biotech On The Hunt For Results In 2023Seeking Alpha • 04/28/23
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology ResearchGlobeNewsWire • 04/19/23
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/23/23
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/23
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023GlobeNewsWire • 03/16/23
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023GlobeNewsWire • 03/15/23
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330GlobeNewsWire • 02/24/23
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/07/23
Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/10/22
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 11/10/22
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/22
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor ConferencesGlobeNewsWire • 11/07/22
Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid TumorsGlobeNewsWire • 09/01/22
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/11/22
Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/03/22